https://www.live-feeds.com/feed/novo-nordisk-shares-jump-6-after-lifting-2026-outlook-on-obesity-drug-demandContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-shares-jump-6-after-lifting-2026-outlook-on-obesity-drug-demandhttps://www.live-feeds.com/feed/novo-nordisk-shares-jump-6-after-lifting-2026-outlook-on-obesity-drug-demand#u191126Tue, 10 Nov 2026 12:25:43 +0000Novo Nordisk shares climbed up to 6% following a third-quarter earnings beat and an upward revision to its full-year 2026 financial outlook. The Danish pharmaceutical company reported third-quarter sales of DKK 79,195 million and net income of DKK 16,740 million. Strong global demand for obesity and diabetes treatments, particularly the oral Wegovy pill, drove the positive results. The oral medication exceeded initial expectations by capturing a dominant share of new US obesity drug prescriptions. Management also accelerated the international rollout of the pill across more than 20 countries.W